Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
TP1563 |
Gap19
|
Gap Junction Protein | Cytoskeletal Signaling |
Gap19 是一种衍生自 Cx43 细胞质环九个氨基酸的肽,是选择性连接蛋白 43 半通道阻滞剂。它可以防止 C 末端与 CL 的分子内相互作用,具有保护心肌作用。 | |||
T23920 |
CX4338
CX-4338,CX 4338 |
Others | Others |
CX4338 is a CXCL8-mediated chemotaxis inhibitor. | |||
T16790L |
Rotigaptide TFA(355151-12-1 free base)
Rotigaptide TFA |
Gap Junction Protein | Cytoskeletal Signaling |
Rotigaptide TFA(355151-12-1 free base) 是一种新型的 Cx43 特异性调节剂,是一种有效的 AAP。 Rotigaptide 可防止 Cx43 介导的间隙连接通讯的解偶联,并使急性代谢应激期间的细胞间通讯正常化。 | |||
TP2110L |
TAT-Gap19 acetate
|
Gap Junction Protein | Cytoskeletal Signaling |
TAT-Gap19 acetate 是 connexin43 hemichannel (Cx43 HC) 的特异性抑制剂。 它穿过血脑屏障并减轻小鼠的肝纤维化。它不抑制相应的 Cx43 GJC。 | |||
T41204 |
TAT-Gap19(I130A)
TAT-Gap19(I130A) |
Others | Others |
TAT-Gap19(I130A) is a control peptide for TAT-Gap19, a Cx43 hemichannel blocker. TAT-Gap19(I130A) consists of TAT-GAP19 with a I130A amino acid residue change at a key residue for GAP19 activity. In C6 glioma cells expression Cx43, TAT-GAP19(1130A) does not inhibit [Ca2+]i-triggered ATP release at 200 μM. TAT-Gap19(I130A) is cell permeable. | |||
TP1511 |
Gap19 TFA (1507930-57-5 free base)
Gap19 TFA |
||
Gap19 TFA is a peptide derived from nine amino acids of Cx43 cytoplasmic ring (CL), an effective, selective connexin 43 (Cx43) half-channel blocker. | |||
T75821 |
TAT-Gap19 TFA
|
||
TAT-Gap19 TFA为Cx模拟肽,特异性抑制connexin43半通道(Cx43 HC),但不影响相应的Cx43 GJC。该化合物具备透过血脑屏障功能,能够减轻小鼠肝纤维化。 | |||
T16790 |
Rotigaptide
ZP123 |
Others | Others |
Rotigaptide is a novel and specific modulator of Cx43 and is a potent AAP. Rotigaptide prevents the uncoupling of Cx43-mediated gap junction communication and normalizes cell-to-cell communication during acute metabolic stress. | |||
T75820 |
Gap19 TFA
|
||
Gap19 TFA,源自Cx43胞浆环(CL)的九个氨基酸肽,是高效且选择性的连接蛋白43 (Cx43) 半通道阻滞剂。该肽阻止C末端(CT)与CL之间的分子内相互作用,但不影响GJ通道或Cx40/pannexin-1半通道。此外,Gap19 TFA对心肌有保护作用。 | |||
TP2110 |
TAT-Gap19
|
||
Cx43 hemichannel blocker (IC50 ~7 μM). No significant affinity for gap junctions or Panx1 channels. N-terminal transactivator of transcription (TAT) motif promotes membrane permeability and increases inhibitory effect of Gap19. Active in vivo. Brain penet | |||
T83682 |
Tat-Gap 19 TFA
|
||
Tat-Gap 19是一种针对连接蛋白43 (Cx43) 半通道的肽抑制剂,由HIV-1 Tat蛋白传导域与对应于Cx43第128-136残基的九氨基酸肽连接而成。Tat-Gap 19 (10 µM) 能够抑制初级大鼠肝细胞中由谷氨酸引发的ATP释放,这是Cx43半通道活性的标志。在通过中脑动脉堵塞(MCAO)诱导的小鼠脑缺血再灌注损伤模型中,以25 mg/kg的剂量进行给药,可减少梗死体积。腹腔内注射Tat-Gap 19 (1 mg/kg 每天) 能够减少硫代乙酰胺引起的小鼠肝损伤模型中的纤维化病灶面积及表达α-平滑肌肌动蛋白 (α-SMA) 的肝星状细胞(成纤维细胞的前体)面积,并提高同种小鼠分离的肝细胞中超氧化物歧化酶 (SOD) 活性。 |